C. Kent Osborne

43.0k citations

173 papers · 25.4k indexed · 10 hit papers · h-index 79

Cancer Research top 0.05%
- Breast Cancer Treatment Studies 37
Oncology top 0.05%
- HER2/EGFR in Cancer Research 76
- Cancer Treatment and Pharmacology 18
- Cancer-related Molecular Pathways 11
Genetics top 0.05%
- Estrogen and related hormone effects 71
Molecular Biology top 0.2%
Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 15
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 22
Endocrinology, Diabetes and Metabolism
- Growth Hormone and Insulin-like Growth Factors 11

Co-authors: Rachel Schiff Gary M. Clark D. Craig Allred Richard Elledge Susan G. Hilsenbeck Carlos L. Arteaga Grazia Arpino Gary C. Chamness
Cited by: Cancer Research Oncology Genetics
Journals: New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (1 paper)The Lancet (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

C. Kent Osborne

169 papers receiving 24.8k citations

Hit Papers

10 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2014 Clinical Cancer Research
2011 Nature Reviews Clinical Oncology
2010 Annual Review of Medicine
2008 JNCI Journal of the National Cancer Institute
2003 JNCI Journal of the National Cancer Institute
2003 Journal of Clinical Oncology
1999 Journal of Clinical Oncology
1998 New England Journal of Medicine
1993 JNCI Journal of the National Cancer Institute
1980 Cancer

Peers

Countries citing papers authored by C. Kent Osborne

Since Specialization

Citations

This map shows the geographic impact of C. Kent Osborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Kent Osborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Kent Osborne more than expected).

Fields of papers citing papers by C. Kent Osborne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Kent Osborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Kent Osborne. The network helps show where C. Kent Osborne may publish in the future.

Co-authorship network

The 25 scholars most cited alongside C. Kent Osborne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Kent Osborne Line = papers co-authored together C. Kent Osborne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis Clinical Cancer Research ·Grazia Arpino,Juan de la Haba-Rodríguez,Jean-Marc Ferrero,Sabino De Placido,C. Kent Osborne,Dirk Klingbiel,Valentine Revelant,Christine Wohlfarth,Raf Poppe,Mothaffar F. Rimawi,(unknown)	2023	25
2	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial Journal of Clinical Oncology ·Mothaffar F. Rimawi,Jean-Marc Ferrero,Juan de la Haba-Rodríguez,Christopher Poole,Sabino De Placido,C. Kent Osborne,Roberto Hegg,Valerie Easton,Christine Wohlfarth,Grazia Arpino,(unknown)	2018	142
3	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance Molecular Cancer Research ·Luca Malorni,Mario Giuliano,Ilenia Migliaccio,Tao Wang,Chad J. Creighton,Mathieu Lupien,Xiaoyong Fu,Susan G. Hilsenbeck,Nuala Healy,Carmine De Angelis,Abhijit Mazumdar,Meghana V. Trivedi,Suleiman Massarweh,Carolina Gutiérrez,Sabino De Placido,Rinath Jeselsohn,Myles Brown,Powel H. Brown,C. Kent Osborne,Rachel Schiff	2016	31
4	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival Cancer Research ·Petra den Hollander,Kathryn Rawls,Anna Tsimelzon,Jonathan H. Shepherd,Abhijit Mazumdar,Jamal Hill,Suzanne A.W. Fuqua,Jenny C. Chang,C. Kent Osborne,Susan G. Hilsenbeck,Gordon B. Mills,Powel H. Brown	2016	70
5	Targeting HER2 for the Treatment of Breast Cancer Annual Review of Medicine ·Mothaffar F. Rimawi,Rachel Schiff,C. Kent Osborne	2015	208
6	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancerbreakdown → Clinical Cancer Research ·Matthew D. Burstein,Anna Tsimelzon,Graham M. Poage,Kyle R. Covington,Alejandro Contreras,Suzanne A.W. Fuqua,Michelle I. Savage,C. Kent Osborne,Susan G. Hilsenbeck,Jenny C. Chang,Gordon B. Mills,Ching C. Lau,Powel H. Brown	2014	936
7	Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer The Breast ·Xiaoyong Fu,C. Kent Osborne,Rachel Schiff	2013	64
8	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 Journal of Clinical Oncology ·Mothaffar F. Rimawi,Ingrid A. Mayer,Andres Forero,Rita Nanda,Matthew P. Goetz,Angel Rodriguez,Anne C. Pavlick,Tao Wang,Susan G. Hilsenbeck,Carolina Gutiérrez,Rachel Schiff,C. Kent Osborne,Jenny C. Chang	2013	187
9	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up Breast Cancer Research and Treatment ·Luca Malorni,Priya B. Shetty,Carmine De Angelis,Susan G. Hilsenbeck,Mothaffar F. Rimawi,Richard Elledge,C. Kent Osborne,Sabino De Placido,Grazia Arpino	2012	175
10	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts Clinical Cancer Research ·Mothaffar F. Rimawi,Lisa Wiechmann,Yen-Chao Wang,Catherine Huang,Ilenia Migliaccio,Meng-Fen Wu,Carolina Gutiérrez,Susan G. Hilsenbeck,Grazia Arpino,Suleiman Massarweh,Robin Ward,Robert Soliz,C. Kent Osborne,Rachel Schiff	2010	66
11	Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice JNCI Journal of the National Cancer Institute ·Tracy E. Strecker,Qiang Shen,Yun Zhang,Jamal Hill,Yuxin Li,Chunyu Wang,Hee-Tae Kim,Tona M. Gilmer,K. Sexton,Susan G. Hilsenbeck,C. Kent Osborne,Powel H. Brown	2009	41
12	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function Cancer Research ·Suleiman Massarweh,C. Kent Osborne,Chad J. Creighton,Lanfang Qin,Anna Tsimelzon,Shixia Huang,Heidi L. Weiss,Mothaffar F. Rimawi,Rachel Schiff	2008	375
13	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts Cancer Research ·Chad J. Creighton,Suleiman Massarweh,Shixia Huang,Anna Tsimelzon,Susan G. Hilsenbeck,C. Kent Osborne,Jiang Shou,Luca Malorni,Rachel Schiff	2008	101
14	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapybreakdown → JNCI Journal of the National Cancer Institute ·X. Li,Michael T. Lewis,Jian Huang,Carolina Gutiérrez,C. Kent Osborne,M.-F. Wu,S. G. Hilsenbeck,Anne C. Pavlick,Xiaolei Zhang,Gary C. Chamness,Hiu Yung Wong,Jeffrey M. Rosen,Jenny C. Chang	2008	1418
15	Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. PubMed ·Rachel Schiff,Suleiman Massarweh,Jiang Shou,C. Kent Osborne	2003	250
16	Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancerbreakdown → Journal of Clinical Oncology ·Jennet Harvey,Gary M. Clark,C. Kent Osborne,D. Craig Allred	1999	1630
17	HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. PubMed ·Richard Elledge,S Green,Daniel R. Ciocca,R Pugh,D. Craig Allred,Gary M. Clark,Julian B. Hill,Peter M. Ravdin,Joe M. O’Sullivan,Silvana Martino,C. Kent Osborne	1998	203
18	The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. The EMBO Journal ·D. L. Stein,Jian Wu,Suzanne A.W. Fuqua,Chan Roonprapunt,Vijay Yajnik,Peter D’Eustachio,John J. Moskow,Arthur M. Buchberg,C. Kent Osborne,Ben Margolis	1994	206
19	Tumor Biologic Factors and Breast Cancer Prognosis Among White, Hispanic, and Black Women in the United States JNCI Journal of the National Cancer Institute ·Richard Elledge,Gary M. Clark,Gary C. Chamness,C. Kent Osborne	1994	357
20	Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer Human Pathology ·D. Craig Allred,Gary M. Clark,Rafael Molina,Atul K. Tandon,Stuart J. Schnitt,Kennedy W. Gilchrist,C. Kent Osborne,Douglass C. Tormey,William McGuire	1992	329

About C. Kent Osborne

C. Kent Osborne is a scholar working on Oncology, Cancer Research and Genetics, having authored 173 papers that have together received 25.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (76 papers), Estrogen and related hormone effects (71 papers), Breast Cancer Treatment Studies (37 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Cancer Treatment and Pharmacology (18 papers), Advanced Breast Cancer Therapies (15 papers), Growth Hormone and Insulin-like Growth Factors (11 papers) and Cancer-related Molecular Pathways (11 papers). The work is most often cited by research in Cancer Research (8.8k citations), Oncology (14.8k citations) and Genetics (8.7k citations). C. Kent Osborne has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Rachel Schiff, Gary M. Clark, D. Craig Allred, Richard Elledge, Susan G. Hilsenbeck, Carlos L. Arteaga, Grazia Arpino, Gary C. Chamness, Suzanne A.W. Fuqua and Jennet Harvey. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact